Tumor cell-derived TGF-β acts on CTLs to specifically repress the expression of perforin, granzyme B, and FasL and to reduce the production of IFN-γ, resulting in a significant attenuation of CTL-mediated tumor cytotoxicity [26]. The gene discussed is FASLG; the disease is neoplasm.